Compare Crispr Therapeutics AG (CRSP) vs J B Hunt Transport Services Inc (JBHT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs J B Hunt Transport Services Inc — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while J B Hunt Transport Services Inc trades at $229.26 (market cap $21.45B). The key difference: J B Hunt Transport Services Inc is far larger — about 4.4× Crispr Therapeutics AG's market cap, and J B Hunt Transport Services Inc pays a 0.79% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and J B Hunt Transport Services Inc for 46 Days on average.
| CRSP | JBHT | |
|---|---|---|
Market Cap | $4.88B | $21.45B |
Volume | 2,861,747 | 1,028,680 |
Sector | Health | Industrials |
52-Week High | $73.97 | $298.41 |
52-Week Low | $44.34 | $137.09 |
Typical Hold Time | 77 Days | 46 Days |
Enterprise Value | $3.30B | $22.59B |
Dividend Yield | — | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
JBHT trades at $228.42, up 2.6% with strong earnings beats in recent quarters. Technical indicators show bearish momentum with support at $225 and resistance at $230. The company maintains solid fundamentals with $12B revenue, 5.31% net margin, and 18.45% ROE, though valuation metrics appear elevated with P/E of 32.5. Recent news highlights ongoing securities investigations and Q3 earnings anticipation.
Outlook remains cautiously optimistic with analyst consensus price target of $289.40 (27% upside) and 59% buy ratings. Key risks include legal investigations, cost pressures from diesel prices, and competitive trucking industry. Earnings growth and freight demand provide catalysts, but legal overhang warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →
